ISB has won a 2025 AWS Imagine Grant to advance Tarpon, a generative AI platform that generates digital fingerprints of T cell receptors. By linking immune signatures to genomic and clinical data, Tarpon enables rapid discovery and the design of targeted therapies.
At a recent virtual town hall, leaders of the Pacific Northwest RECOVER hub shared what they’ve learned so far about long COVID — from symptom trajectories and genetic risk to early trial results and upcoming studies — and answered questions from participants about risk factors, persistent symptoms and what comes next.
Researchers from the NIH-funded RECOVER study shared new insights on the risks of Long COVID, autoimmune links, and upcoming clinical trials during ISB’s July Town Hall.
In a Research Roundtable presentation and Q&A, ISB President Dr. Jim Heath shared how his team is using generative AI to unlock new understanding of human immunity, and how these discoveries could help predict disease severity, improve cancer therapies, and more.
Co-Author Craig Mundie and ISB’s Dr. Jim Heath discuss AI’s rapid evolution, ethical considerations, and potential to revolutionize science and society in a compelling Town Hall event.
ISB hosted a virtual event to share updates on the ongoing RECOVER study, a national NIH-funded initiative to understand and address Long COVID.
In a breakthrough discovery that changes how we understand T cells and with implications of how we can better engineer custom immune responses to fight disease, Institute for Systems Biology researchers showed that the different disease-fighting functions of different T cells are determined by the genetically encoded T-cell receptor sequence that are unique to those cells.
Renowned artist Ginny Ruffner and ISB President Dr. Jim Heath delivered a lecture at Town Hall Seattle about the intersection of art and science. They spoke about how creation stories tie scientists and artists together, and how their approaches are both similar and different from that point on.